UnitedHealth Group Incorporated

Brookfield Renewable Corporation

Norfolk Southern Corporation

They are shifting their focus to health care, manufacturing and materials, which benefit from structural changes in the economy

AI stocks have come under pressure. Which sectors are now favored by managers?

Vertex Pharmaceuticals Incorporated

Techno-billionaires from Silicon Valley are actively <a href="https://oninvest.com/article/magnaty-kremnievoj-doliny-delaut-stavki-na-omolozenie-mozno-li-na-etom-zarabotat">investing</a> in finding new ways to extend life. However, they are not only concerned about this - in San Francisco, with the support of OpenAI CEO Sam Altman and Coinbase CEO Brian Armstrong, a startup called Preventive has been secretly <a href="https://www.wsj.com/tech/biotech/genetically-engineered-babies-tech-billionaires-6779efc8">working</a> <a href="https://www.preventive.bio/blog/announcing-preventive">for</a> six months to create genetically "improved" babies using the latest DNA editing technologies. And he's not the only one. The idea is a noble one - to rid people of genetic diseases, but critics fear both failure and success of this venture.

Human 2.0: where Silicon Valley's attempt to rewrite DNA is headed

Evommune, Inc.

The market value of the company, based on the listing results, was estimated at more than $480 billion

Evommune IPO: shares in atopic dermatitis treatment developer become available

Novo Nordisk A/S

Pfizer Inc.

Novo Nordisk, the maker of obesity drugs Wegovy and Ozempic, and US pharma company Pfizer have improved their offers to buy US startup Metsera, which develops weight-loss drugs. The company itself still considers Novo's offer "more favorable" despite the escalating battle for the deal, the Financial Times <a href="https://www.ft.com/content/ab202cb5-ee27-4257-b2ee-431408c970c1">writes</a>.

Novo Nordisk and Pfizer raise stakes in battle for weight loss drug developer

Abbott Laboratories

Air Products and Chemicals, Inc.

Johnson & Johnson

Generac Holdings Inc.

ITT Inc.

Marex Group plc

Amazon.com, Inc.

GitLab Inc.

NVR, Inc.

Barrick Mining Corporation

Anglo American plc

Sibanye Stillwater Limited

AI is a risky strategy, real production is a conservative one: Oninvest asked Astero Falcon portfolio manager Alena Nikolaeva where to invest $10,000 if the horizon is about a year and the goal is to increase capital. Two strategies include companies from the "old" economy.

Where to invest $10,000 right now: the renaissance of real manufacturing 

Regeneron Pharmaceuticals, Inc.

The 2025 Nobel Prize in Physiology or Medicine <a href="https://www.nobelprize.org/prizes/medicine/2025/press-release/">was awarded to</a> Mary E. Bruncoe, Fred Ramsdell and Shimon Sakaguchi for discoveries in the workings of the immune system that pave the way for treatments for autoimmune diseases and cancer, as well as easier organ transplantation. The mechanism they discovered is called peripheral immune tolerance - sounds confusing, let's figure it out.

Rabbits vs. scientific dogma: what you need to know about the Nobel Prize in Medicine

The fact that artificial intelligence is used in almost all spheres of human life is no surprise to anyone. But the case of Albania, where the first virtual minister appeared in September this year and was allowed to distribute public finances, raises many important questions. Among them is how actively AI should be involved in government management and how it should be controlled. Vadim Novikov, Advisor to the President of Almaty Management University (AlmaU), discusses this.

The Altar of Power and the Machine: Will Artificial Intelligence Replace the State?

Cronos Group Inc.

Canopy Growth Corporation

Tilray Brands, Inc.

An exchange-traded fund tracking the industry has fallen 90% in price since the peak of investment in marijuana growers

Trump released a video about marijuana products. Producers' stocks went up

Ionis Pharmaceuticals, Inc.

Quotes of biotech Ionis Pharmaceuticals jumped 35% in a single day after it announced a successful trial of a drug that reduces triglyceride levels in the blood and prevents cases of acute pancreatitis. Analysts were positive about the results. The company, which is known for its Spinraza drug for spinal muscular atrophy, could see its shares rise another 40%, according to some analysts' models.&nbsp;

Biotech Ionis Pharmaceuticals surges 35% after upbeat trial of triglyceride drug

Silvergate Capital Corporation

Shares of Shoulder Innovations, a small-cap maker of shoulder implants, <a href="https://finance.yahoo.com/quote/SI/">surged</a>&nbsp;more than 18% yesterday, August 25, after at least four Wall Street analysts <a href="https://www.cnbc.com/2025/08/25/goldman-says-this-specialized-medical-implant-stock-has-more-than-50percent-upside.html">initiated </a>coverage with bullish calls. Goldman Sachs, for example, set a target price that implies upside of more than a third.

Four banks initiate coverage with 'buy' call on Shoulder Innovations; shares soar

Tesla, Inc.

Meta Platforms, Inc.

In mid-August, it became known that OpenAI CEO Sam Altman intends to <a href="https://www.ft.com/content/04484164-724e-4fc2-92a2-e2c13ea639bd">back</a> Merge Labs, a company that is developing a brain-computer interface - a class of technology that allows people to control computers using neural signals from the brain, i.e., actually by the power of thought. This further intensifies competition with his former partner and now rival Elon Musk, who launched a similar startup, Neuralink, in 2016. So far, the technology is being used with the noble goal of helping completely paralyzed people to communicate with the world around them again by controlling computer interfaces. However, both billionaires believe that in the long run, this technology will literally save humanity from extinction.

The great merger: why billionaires are getting in our heads

Heartflow, Inc.

The company raised $316.7 million, more than it had expected